ATOS — Atossa Therapeutics Share News
0.000.00%
Last trade - 00:00Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of $1.08 a share - Earnings Preview
Atossa Therapeutics Q2 net loss widens on lower interest income
Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses
Brief: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome
Brief: Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Atossa Therapeutics Receives FDA "Study May Proceed" Letter For (Z)-Endoxifen
Atossa Therapeutics Q3 net loss widens as operating costs rise
Health Rounds: Scientists find way to make breast cancer drug work better for younger women
Brief: Atossa Therapeutics - Appoints Mark Daniel As CFO - SEC Filing
Brief: Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities